Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland

Page created by Kevin Herrera
 
CONTINUE READING
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Marjo Taal & Hanna Bos
26 juli 2018
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Synergie in de soa-bestrijding

Wat gaat er goed in de NL soa-
bestrijding en waar ben jij trots
op?
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Syndemics….. synergie!

                 https://www.rivm.nl/en/Topics/S/Sexually_transmitted_infecti
                 ons_STIs/Video/Video_STI_s.std?ext=.mp4
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Programma

1.   Start-up
2.   Syfilis
3.   Soa en PrEP?
4.   Soa kliniek in the
     future
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Synergie
Disease Concentration

                           Disease interaction

                    Large scale social forces
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
6

Gonorrhea in the U.S - 2016
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
HIV and STI Synergy

                       Inflammation and/or
                             ulceration

      BEHAVIOR           Condomless sex                            ↑HIV
STI                                                PrEP and
                         Multiple partners                      transmission
                                                     TasP     and/or acquisition

                    Higher risk partners, ↑ risk
                    of HIV-infected partner
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
HIV and STI Synergy

                       Inflammation and/or
                             ulceration

                                                                   ↑HIV
      BEHAVIOR           Condomless sex                         transmission
STI                                                PrEP and
                         Multiple partners                    and/or acquisition
                                                     TasP

                    Higher risk partners, ↑ risk
                    of HIV-infected partner
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
•   it‘s the mucosa/microbioom!

• DGI: gedissimineerde gonorroe
   go vaccin & China

• MSM migrants: prioriteit PrEP

• HCV eliminatie: gedragsverandering!
Marjo Taal & Hanna Bos 26 juli 2018 - Soa Aids Nederland
Syfilis
Congenital Syphilis Cases by Year of Birth and
rates of Primary and Secondary Syphilis among Women, United
States, 2007–2016

Source: Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
Decline in the number of penicillin API manufacturers
    over the past decade, 1995-2018
                                                  Pre-1995    1995-2000
                                                                 1995-      2001-2005
                                                                               2001-    2006-2010
                                                                                           2006-      2011-2015
                                                                                                         2011-       2016
                                                   Pre-1995                                                            Current
                                                                  2000         2005          2010          2015

    •    CSPC                       China

    •    NCPC                       China

    •    Jiangxi Dongfeng           China

    •    Sandoz                     Germany                                                           Closed plant

                                                                                        Acquired by
    •    Wyeth                      India                                               Pfizer
                                                                                        Acquired by
    •    King                       USA                                                 Pfizer
                                                                                                      Ended
    •    Pfizer                     USA                                                               production
                                                                                                      Ended
    •    Alembic                    India                                                             production
                                                                                        Ended
    •    Bristol Europe             UK                                                  production
                                                                                                      Ended
    •    Aventis                    France                                                            production
                                                              Acquired by
    •    GIST Brocades              Netherlands               DSM*

Source: Melanie Taylor, RHR/STI, WHO Geneva.
A Vicious Cycle: STDs predict future HIV Risk

Rectal GC
or CT
                1 in 15 MSM were diagnosed with HIV within 1 year.*
Primary or
Secondary
Syphilis        1 in 18 MSM were diagnosed with HIV within 1 year.**
No rectal STD
or syphilis
infection

                1 in 53 MSM were diagnosed with HIV within 1 year.*
                                              *STD Clinic Patients, New York City. Pathela, CID 2013:57;
                               **Matched STD/HIV Surveillance Data, New York City. Pathela, CID 2015:61
Syfilis

Toepassing in jouw werk?
Vragen aan experts?
Vragen aan andere disciplines?
PrEP en soa
Risk Compensation adjustment of behaviour in response to a
perceived reduction in risk.

•Critical issue in the public health implementation of biomedical interventions: Could increased risky
sexual behavior counteract the biological efficacy against HIV?

•Behavioral adaptation: Behavioral changes triggered by a safety measure: reduction in condom use
•Behavioral disinhibition: Lack of restraint with more risk taking behaviors: increasing nr of partners,
nr of sexual acts, chemsex…

•STIs: Best objective measure of risk compensation and most feared consequence of risk compensation
•Individual vs. population impact of biomedical interventions: risk compensation among people not
using PrEP/TASP

•Risk management plan: Assess the public health impact of PrEP
                                            Cassell BMJ 2006
Figure 10
New diagnoses of HIV and STIs from 1996
to 2015 in MSM in England

                              Unemo M et al. Lancet Infect Dis 2017
Unemo M et al. Lancet Infect Dis 2017
Community-Level Changes   in11Condom use with
                      Figure
Casual Partners Among MSM

               30%
               1%

               46%

   The Lancet Infectious Diseases 2017 17, e235-e279DOI: (10.1016/S1473-3099(17)30310-9)
   Copyright                                                                               Holt M. et al . Lancet HIV 2018
Meta-analyis of effect of PrEP on STIs
diagnosis among MSM

 Significant increase in any rectal STI diagnosis (OR: 1.39, 95% CI: 1.03-1.87)
 Significant increase in rectal chlamydia (OR: 1.59, 95% CI: 1.19-2.13)
 Increase in STIs rates in more recent studies (OR: 1.47, 95% CI: 1.05-2.05) Traeger MW et al. CID 2018
Partners, not condom use drive STIs rates
   • SPARK: Community-based PrEP demonstration project in NYC
   • 261 MSM followed until M12 after PrEP intitiation
   • Decrease in condom use: 61% to 46%

        Predicting Factors of STIs   aOR          95% CI               p

 Age < 25 years old                   3.67       1.11-12.25          < 0.05
 > 5 casual partners at BL            2.80       1.43-5.50           < 0.01
 STIs in 6 months pre-PrEP            2.22       1.07-4.59
PrEP en soa

Toepassing in jouw werk?
Vragen aan experts?
Vragen aan andere disciplines?
STI clinic in the future Dean Street Express, London
Time to treatment
                              Pre Express          Post Express

Time attendance to informed
of result (hours)                   183                   3.8

Time attendance to
treatment                           238                    48
(hours)

                              Byrne et al, BASHH oral presentation 2015

                                    Whitlock et al, Int J STD&AIDS 2018
CT/GC in HIV negative MSM
         15.000      Chlamydia any site                                                                                                                                                                        1.000

                                                                                                                                                                                                                         Diagnoses
                                                                                                                                                                                                               800
 Tests
         10.000
                                                                                                                                                                                                               600

                                                                                                                                                                                                               400
          5.000
                                                                                                                                                                                                               200

             -                                                                                                                                                                                                 -
                      1       2       3       4       1       2       3       4       1       2       3       4       1       2       3       4       1       2       3       4       1        2       3
                              2012
                                                      Chlamydia
                                                         2013
                                                                diagnoses
                                                                    2014
                                                                                                                              Chlamydia
                                                                                                                              2015
                                                                                                                                        tests
                                                                                                                                          2016                                                2017

                     Gonorrhoea any site
         15.000                                                                                                                                                                                                    2.000

                                                                                                                                                                                                                            Diagnoses
                                                                                                                                                                                                                   1.500
 Tests

         10.000
                                                                                                                                                                                                                   1.000
          5.000
                                                                                                                                                                                                                   500

                 -                                                                                                                                                                                                 -
                          1       2       3       4       1       2       3       4       1       2       3       4       1       2       3       4       1       2       3       4       1        2       3
                     2012       Gonorrhoea
                                     2013       diagnoses
                                                   2014             Gonorrhoea2016
                                                                  2015               tests      2017
    HIV and STI test and diagnosis trends in MSM attending Dean Street Clinic, 2012 to 2016 (GUMCAD)
STI models of care
Private                                Public
Pro’s                                   Pro’s
• High coverage                          • Serve high-risk populations
• Can easily provide basic STI screening • Diagnose and treat large numbers of
  services                                 STIs
Contra’s                                 • High level of expertise
• Most patients not at high risk        Contra’s
• STIs not a priority                   • Low coverage
• Lack of expertise                     • Stigma
Public Health Impact                    Public Health Impact
• Generalized epidemics                 • Concentrated epidemics
Concentrated Epidemics

                 Most of these infections are
HIV              overlapping epidemics among
                 populations that STD clinics have
Syphilis         access to:
Gonorrhea         •
                  •
                      MSM
                      Sex workers
LGV               •
                  •
                      injection drug users
                      other high-risk populations
Hepatitis C
Online services: SH24
                 Mobile friendly and online
Digital vending machine
BioSURE HIV self-tests: 3rd generation
Wall mounted at eye level
Touch screen
Robust - liquid proof – secure (>300 machines,
no incidents)
Lifespan ‘hundreds of thousands’ of vends
Little maintenance, can be done remotely
Access website for live monitoring of sales,
issues and epidemiological data                  Installed Brighton Sauna
                                                 June 2017
GPS to predict the next event

You probably met gonorroea at …..
Your nearest STI care that is open now is…….
STI clinic in the future
∞ Social media
campaigns                                                Branded services
                                                         tailored to diverse
Tailored risk reduction                                  needs
advice online
                                                         Outreach in hot spots
Links to community                                       and/or to support
organisations                                            local community needs

 Wellbeing programme
                                         Self-sampling

                          Self-testing
Barriers
 Funding constraints
   • a small pot for prevention
   • complacency amongst policy-makers/funders/…

 Provider constraints
    slow to adopt new technologies, resistant to change,
     paternalistic
    not knowing/connecting with users
    negative attitudes persist

 Population constraints
    fear and stigma have not gone away
Solutions
 Funding constraints
   • tackle the cost of tests – a global issue
   • make throughput efficient for lab (upscale) and clinic
     (differentiate)

 Provider constraints
    top-down, bottom-up – create the team that gets the
     technology
    keep it lively – refresh campaigns, start new ones, reward
     staff, trust the users

 Population constraints
    work with community champions on positive messages –
     be inclusive, celebrate diversity
STI clinic in the future
Toepassing in jouw werk?
Vragen aan experts?
Vragen aan andere disciplines?
You can also read